Luigi Pontieri

Keyphrases

1. Multiple Sclerosis 100%
2. Multiple Sclerosis Treatment 31%
3. Denmark 31%
4. National Cohort Study 30%
5. Annualized Relapse Rate 29%
6. Expanded Disability Status Scale 28%
7. Disease-modifying Therapy 27%
8. Relapsing-remitting multiple Sclerosis 27%
9. Progressive MS 27%
10. Disease Activity 24%
11. Data Networks 22%
12. Relapsing-remitting MS 22%
13. Progressive multiple Sclerosis 18%
14. Confidence Interval 14%
15. Danish Population 12%
16. Adverse Events 12%
17. COVID-19 Vaccination 11%
18. Natalizumab Treatment 11%
19. Population-based Cohort Study 11%
20. Ocrelizumab 11%
21. Registry Research 11%
22. Socioeconomic Status 11%
23. Treatment Switching 11%
24. Treatment Predictors 11%
25. Clinical Disease Activity 11%
26. Fingolimod 11%
27. Relapse Pattern 11%
28. Prognostic Factors 11%
29. Teriflunomide 11%
30. Newly Diagnosed 11%
31. Europe 11%
32. International Registry 11%
33. Health Systems 11%
34. Cladribine 11%
35. Life Perspectives 11%
36. Real-world Experience 11%
37. European Registries 11%
38. Clinical Disease 11%
39. Single-center Study 11%
40. Clinical Diagnosis 11%
41. MS Diagnosis 11%
42. Multiple Sclerosis MS 9%
43. Sweden 9%
44. Disease Risk 9%
45. Relapse Risk 9%
46. Natalizumab 9%
47. MS Patients 8%
48. Disability 6%
49. Diagnostic Uncertainty 6%
50. Disease Course 6%